Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.39 |
| ▸ | BUB1 | O43683 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.36 |
| ▸ | DDX3X | O00571 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3051840 | 0.81 | TSHR (0.37) | MAPK14MEN1MAPTKMT2ATDP1 | |
| SCHEMBL3051914 | 0.81 | MAPK14 (0.39) | MAPK14 | |
| SCHEMBL27706506 | 0.81 | KIF11 (0.57) | KDM4EMEN1LMNAGAAMAPT | |
| SCHEMBL3051761 | 0.81 | AKR1C3 (0.47) | MAPK14MEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL5285564 | 0.80 | MAPK14 (0.38) | MAPK14RAPGEF4 | |
| SCHEMBL5296159 | 0.80 | MAPK14 (0.45) | MAPK14 | |
| SCHEMBL20950906 | 0.79 | CASP1 (0.47) | KDM4EMEN1LMNAGAAMAPT | |
| SCHEMBL27706509 | 0.78 | MAPK14 (0.34) | MAPK14 | |
| SCHEMBL3059142 | 0.78 | MAPK14 (0.64) | MAPK14KMT2ATDP1 | |
| SCHEMBL3042003 | 0.77 | NPC1 (0.46) | MAPK14MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007000337-A1 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2007-01-04 | — | — | WO | claimed |
| US-20100222363-A1 | Bicyclic Derivatives as P38 Inhibitors | PALAU PHARMA, S.A. (ES) | 2010-09-02 | — | — | US | disclosed |
| CN-101213175-A | Bicyclic derivatives as p38 kinase inhibitors | PALAU PHARMA SA (ES) | 2008-07-02 | — | — | CN | disclosed |
| EP-1907358-A2 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | Palau Pharma, S.A. (ES) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007000337-A1 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007000340-A2 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222363-A1 | Bicyclic Derivatives as P38 Inhibitors | MAPK1, MAPKAPK2, MAPK7 | MAPK14 21/4885KDM4E 3953/4885MEN1 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.